These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558 [TBL] [Abstract][Full Text] [Related]
7. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970 [TBL] [Abstract][Full Text] [Related]
16. [Mesalazine granules instead of tablets. New ulcerative colitis therapy confirmed also in general practice routine]. MMW Fortschr Med; 2004 Jun; 146(24):53. PubMed ID: 15366501 [No Abstract] [Full Text] [Related]
17. [Interstitial nephritis associated with mesalazine therapy]. Vuotila M; Ikäheimo R; Pietiläinen T Duodecim; 2003; 119(20):1978-82. PubMed ID: 14640003 [No Abstract] [Full Text] [Related]
18. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894 [TBL] [Abstract][Full Text] [Related]